Orthofix Q4 sales slightly beat expectations, EBITDA beats

Orthofix Medical

24/02/2026 12:12

Overview

Medical technology firm's Q4 net sales slightly beat analyst expectations

Adjusted EBITDA for Q4 beat analyst estimates

Company reported strong free cash flow generation in Q4

Outlook

Orthofix expects 2026 net sales between $850 mln and $860 mln

Company projects 2026 non-GAAP adjusted EBITDA of $95 mln to $98 mln

Orthofix anticipates positive free cash flow for full-year 2026

Result Drivers

GLOBAL SPINE FIXATION - Co reported 10% growth in net sales for Global Spine Fixation, driven by commercial channel optimization

BONE GROWTH THERAPIES - Bone Growth Therapies saw a 7% increase in net sales for Q4 2025

U.S. LIMB RECONSTRUCTION - U.S. Limb Reconstruction reported 8% net sales growth in Q4 2025

Company press release: ID:nBw2gRpwRa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Slight Beat*
$219.90 mln
$218.71 mln (5 Analysts)
Q4 Adjusted EBITDA
Beat
$29.20 mln
$28.39 mln (5 Analysts)
Q4 Gross Margin
71.10%


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Orthofix Medical Inc is $18.00, about 32.5% above its February 23 closing price of $13.59

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)